About TransCure bioServices
TransCure bioServices is a Healthcare company based in Archamps (France) founded in 2012 by Patrick Nef. It operates as a humanized mouse models are developed for preclinical immune drug studies. TransCure bioServices has raised $3.58 million across 6 funding rounds from investors including European Union, Financiere Arbevel and Cathay Capital. Its chief executive is Patrick Nef. TransCure bioServices offers products and services including CD34+ Humanized Mouse, Humanized Liver Mouse, Double Humanized Mouse, and Conventional Mouse Model. Its focus areas include Biopharma Outsourcing, CRO, Preclinical Studies and Diversified. Its competitors include GenOway, PsychoGenics, PharmaLegacy Laboratories, InVivo Biosystems and Noble Life Sciences and 4 more; 4 of its 9 listed competitors have raised funding.
Company details
TransCure bioServices was founded in 2012 in Archamps, France, within the biotechnology sector. Services are provided to pharmaceutical companies, biotechs, and academic labs using the Humanized Immune System (HIS) mouse model. This platform supports drug profiling for immune-related diseases and anti-HIVAIDS therapies. Immunodeficient mouse strains are engrafted with human CD34 hematopoietic stem cells sourced from cord blood.
- Headquarters Archamps, France
- Founders Patrick Nef
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website transcurebioservices.com
- Social LinkedIn
- Total Equity Funding$3.58M (USD)
in 6 rounds
- InvestorsEuropean Union
& 4 more
Products & Services of TransCure bioServices
TransCure bioServices offers a comprehensive portfolio of products and services, including CD34+ Humanized Mouse, Humanized Liver Mouse, Double Humanized Mouse, and Conventional Mouse Model.
Model for human immune system in efficacy testing
For hepatotoxicity and drug evaluation studies
Combines immune and liver systems for research
Standard models for general preclinical work
Funding Insights of TransCure bioServices
TransCure bioServices has successfully raised a total of $3.58M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.58M
- Total Rounds 6
- First Round $10,822
(Jul 2014)
- Investors Count 5
All 6 funding rounds of TransCure bioServices with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2022 | – | Series B | – | – | |
| Jun 2019 | $2.79M | Series A | – | Financiere Arbevel | – |
| Jun 2019 | $55,992 | Grant | – | – | |
| Aug 2014 | $779,387 | Seed | – | – | – |
| Jul 2014 | – | Grant | – | – | |
| Jul 2014 | $10,822 | Seed | – | Savoie Mont Blanc Angels | – |
5 investors in total: 5 institutional.
Investors in TransCure bioServices
TransCure bioServices has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, Financiere Arbevel and Cathay Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Cathay Capital is engaged in global investment and transformation. | – | cathaycapital.com | Paris, France | |
- | – | savoie-mont-blanc-angels.com | - | |
Investment management services are provided for clients in Paris. | 1997 | arbevel.com | Paris, France | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
- | – | eurostars-eureka.eu | - |
Investor details for TransCure bioServices
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of TransCure bioServices
1 people are tracked at TransCure bioServices (1 in leadership).
| Name | Role | Group |
|---|---|---|
Patrick Nef | Founder & CEO | Leadership |
Complete people profiles for TransCure bioServices
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of TransCure bioServices
3 dated milestones of TransCure bioServices across 10 years, from founding to its latest funding, stage changes and deals.
- Founded TransCure bioServices is founded.
- Funding First funding round of $11K.
- Funding Latest funding round, Series B,.
Competitors of TransCure bioServices
TransCure bioServices has 9 listed competitors in our database, 4 of them funded. They include GenOway, PsychoGenics, PharmaLegacy Laboratories, InVivo Biosystems and Noble Life Sciences, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| genoway.com | 1999 | Lyon, France | $11.55M | – | Provider of transgenic rodent models and customized cell lines for preclinical development | |
| psychogenics.com | 1999 | Tarrytown, United States | – | 124 | Preclinical CRO services for CNS and orphan disorders are offered. | |
| pharmalegacy.com | 2008 | Shanghai, China | – | – | Preclinical CRO offering in vivo models and services for a wide range of therapeutic areas | |
| invivobiosystems.com | 2019 | United States | $8.16M | – | Animal models are supplied for in-vivo analytical services. | |
| noblelifesci.com | 2010 | Woodbine, United States | $335,000 | – | Preclinical contract research organization offering standard GLP and non-GLP services | |
| alphagenesisinc.com | 2003 | Yemassee, United States | – | 143 | Company offering primate models and services for preclinical drug discovery | |
| zeclinics.com | 2013 | Barcelona, Spain | – | – | Zebrafish models for toxicity studies are developed by ZeClinics CRO. | |
| specipig.com | 2013 | Barcelona, Spain | $605,119 | – | Biomedical research services using swine models are offered by Specipig. | |
| explorabiolabs.com | 2004 | San Diego, United States | – | – | Discovery pharmacology and vivarium services are provided to biotech clients. |
Detailed competitors of TransCure bioServices
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of TransCure bioServices
The website of TransCure bioServices (transcurebioservices.com) receives about 6.2K visits a month.
- Monthly visits6.2K
▼ 11.9% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
10 companies that operate in the same segment as TransCure bioServices (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Transcure Bioservices
Complete news archive for TransCure bioServices
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TransCure bioServices
TransCure bioServices was founded in 2012 and raised its 1st funding round 2 years after it was founded.
TransCure bioServices is headquartered in Archamps, France. It is registered at Archamps, Haute-savoie, France.
Patrick Nef is the current CEO of TransCure bioServices. They have also founded this company.
TransCure bioServices is a funded company, having raised a total of $3.58M across 6 funding rounds to date. The company's 1st funding round was a Seed of $10.82K, raised on Jul 2014.
TransCure bioServices was founded in 2012 in Archamps, France, within the biotechnology sector. Services are provided to pharmaceutical companies, biotechs, and academic labs using the Humanized Immune System (HIS) mouse model. This platform supports drug profiling for immune-related diseases and anti-HIVAIDS therapies. Immunodeficient mouse strains are engrafted with human CD34 hematopoietic stem cells sourced from cord blood.
TransCure bioServices's top competitors include GenOway, PsychoGenics and Alpha Genesis.
TransCure bioServices offers CD34+ Humanized Mouse, Humanized Liver Mouse, Double Humanized Mouse, and Conventional Mouse Model.
TransCure bioServices has 5 investors. Key investors include European Union, Financiere Arbevel, Cathay Capital, Eurostars, and Savoie Mont Blanc Angels.